Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy.
Torasawa M, Horinouchi H, Nomura S, Igawa S, Asai M, Ishii H, Wakui H, Ushio R, Asao T, Namba Y, Koyama R, Hayakawa D, Katayama I, Matsuda H, Sasaki S, Takahashi K, Hosomi Y, Naoki K, Ohe Y. Torasawa M, et al. J Thorac Oncol. 2024 Feb;19(2):325-336. doi: 10.1016/j.jtho.2023.09.1446. Epub 2023 Sep 23. J Thorac Oncol. 2024. PMID: 37748690 Free article.
Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Jingo K, Harada N, Nishioki T, Torasawa M, Yamada T, Asao T, Takagi H, Takeshige T, Ito J, Takahashi K. Jingo K, et al. Among authors: torasawa m. Allergy Asthma Clin Immunol. 2020 Jun 10;16:46. doi: 10.1186/s13223-020-00446-w. eCollection 2020. Allergy Asthma Clin Immunol. 2020. PMID: 32536947 Free PMC article.
Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.
Shimoda Y, Shibaki R, Yoshida T, Murakami S, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y, Motoi N. Shimoda Y, et al. Among authors: torasawa m. Clin Lung Cancer. 2022 Sep;23(6):477-486. doi: 10.1016/j.cllc.2022.04.001. Epub 2022 Apr 29. Clin Lung Cancer. 2022. PMID: 35644780
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Higashiyama RI, Yoshida T, Yagishita S, Ohuchi M, Sakiyama N, Torasawa M, Shirasawa M, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Hamada A, Ohe Y. Higashiyama RI, et al. Among authors: torasawa m. J Thorac Oncol. 2022 Oct;17(10):1227-1232. doi: 10.1016/j.jtho.2022.06.010. Epub 2022 Jul 3. J Thorac Oncol. 2022. PMID: 35788404 Free article.
Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Shimoda Y, Yoshida T, Miyakoshi J, Torasawa M, Tateishi A, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Shimoda Y, et al. Among authors: torasawa m. Cancer Immunol Immunother. 2023 Aug;72(8):2613-2621. doi: 10.1007/s00262-023-03429-z. Epub 2023 Apr 16. Cancer Immunol Immunother. 2023. PMID: 37062033 Free PMC article.
Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M, Yoshida T, Takeyasu Y, Shimoda Y, Tateishi A, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Ohe Y. Torasawa M, et al. Cancer Med. 2023 Jun;12(11):12388-12401. doi: 10.1002/cam4.5939. Epub 2023 Apr 16. Cancer Med. 2023. PMID: 37062059 Free PMC article.
Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles.
Torasawa M, Horinouchi H, Yagishita S, Utsumi H, Okuda K, Takekoshi D, Ito S, Wakui H, Murata S, Kaku S, Okuma K, Matsumoto Y, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Araya J, Ohe Y, Fujita Y. Torasawa M, et al. Thorac Cancer. 2023 Oct;14(29):2909-2923. doi: 10.1111/1759-7714.15077. Epub 2023 Aug 24. Thorac Cancer. 2023. PMID: 37614219 Free PMC article.
15 results